Trial · NCT02667288
An Open-Label Safety Study of A-101 Solution
NCT02667288, Phase 3, Completed, Aclaris Therapeutics, Inc.; results first posted 2017-11-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An Open-Label Safety Study of A-101 Solution. Trials, record NCT02667288. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02667288
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Open-Label Safety Study of A-101 Solution
- NCT number
- NCT02667288
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 147 participants, actual
- Lead sponsor
- Aclaris Therapeutics, Inc.
- Conditions
- Seborrheic Keratosis
- Interventions
- A-101 Solution
- First posted
- 2016-01-28
- Last updated
- 2018-02-07
- Results first posted
- 2017-11-17
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Subjects With Lesion Clearance | Study day 148 | Proportion of subjects for whom all target lesions were judged to be clear on the Physician Lesion Assessment (PWA) Scale. The PWA scale is a 4 point scale used by the investigator to assess each subject target SK Lesion. |
| Secondary | Per Subject Percent of Lesion Clearance | Day 148 | Physician Lesion Assessment (PWA) average Per-Subject Percent of target lesions judged to be clear at Visit 12 in the per protocol population. The PWA scale is a 4 point scale used by the investigator to assess the subject's Target SK lesions. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Subjects With Lesion Clearance | Study day 148 | ITT Population | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Per Subject Percent of Lesion Clearance | Day 148 | Per Protocol Population | percentage of lesions cleared | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Subjects With Lesion Clearance | A-101 Solution | 16 | Participants | ||
| Per Subject Percent of Lesion Clearance | A-101 Solution | 28.17 | Standard Deviation 35.34 | percentage of lesions cleared |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | A-101 Solution | 147 | |
| Overall Study | COMPLETED | A-101 Solution | 134 | |
| Overall Study | NOT COMPLETED | A-101 Solution | 13 |
Source ClinicalTrials.gov
Adverse events7
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Cough | Respiratory, thoracic and mediastinal disorders | A-101 Solution | 3 | 147 | 3 |
| other | Seasonal Allergy | Immune system disorders | A-101 Solution | 3 | 147 | 3 |
| other | Sinusitis | Infections and infestations | A-101 Solution | 3 | 147 | 3 |
| other | Actinic Keratosis | Skin and subcutaneous tissue disorders | A-101 Solution | 2 | 147 | 2 |
| other | Anemia | Blood and lymphatic system disorders | A-101 Solution | 2 | 147 | 2 |
| other | Dermatitis Contact | Skin and subcutaneous tissue disorders | A-101 Solution | 2 | 147 | 2 |
| other | Nasopharyngitis | Infections and infestations | A-101 Solution | 2 | 147 | 2 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | A-101 Solution | 0 | 147 |
| Total, other adverse events | A-101 Solution | 14 | 147 |
| Total, serious adverse events | A-101 Solution | 0 | 147 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02667288
GET https://conductscience.org/api/trials/v1/NCT02667288/registered